文献速递肿瘤 PET/CT

基线与残留TMTV的个体化阈值影响复发难治性淋巴瘤的治疗反应与结局:GATA研究结果

Personalized baseline and residual TMTV influence treatment response and outcomes in relapsed/refractory lymphomas: results from the GATA study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-02-22

GATA研究纳入91例复发难治性弥漫大B细胞淋巴瘤和滤泡性淋巴瘤患者,比较TMTV41%、TMTV4和基于个体化肝脏阈值(pTMTVliver)三种分割方法。基线TMTV越高无进展生存和总生存越短(所有方法p<0.0001);残留pTMTVliver对无进展生存(HR 5.10,C-index 0.724)和总生存(HR 4.00,C-index 0.853)的预后分层优于TMTV4和Deauville评分。

要点

  • 基线TMTV越高,复发难治性淋巴瘤患者的无进展生存和总生存越短(所有方法p<0.0001)。
  • 残留pTMTVliver对无进展生存的预后表现优于TMTV4和Deauville评分(HR 5.10,C-index 0.724)。
  • 残留pTMTVliver对总生存的预后表现优于TMTV4和Deauville评分(HR 4.00,C-index 0.853)。

核心结论

  • 基线和残留TMTV对淋巴瘤患者的预后和治疗反应有强烈影响。
  • 新型个体化pTMTVliver方法提高了患者分层准确性,尤其是对Deauville评分4-5分患者,提供更可靠的风险评估。
  • 需要更大队列验证这些发现并优化基于残留TMTV的临床应用。

研究设计与样本

  • 分析GATA试验中91例复发难治性弥漫大B细胞淋巴瘤和滤泡性淋巴瘤患者。
  • 比较三种分割方法:TMTV41%、TMTV4和pTMTVliver。
  • pTMTVliver采用200%SUVmeanliver阈值,与125%SUVmaxliver一致。

主要发现

  • 基线TMTV显著影响预后,TMTV越高无进展生存和总生存越短(所有方法p<0.0001)。
  • 残留TMTV中,pTMTVliver和TMTV4对未达完全代谢缓解(no-CMR)患者的分层预测误差最低、预测准确性优于TMTV41%。
  • 多因素分析证实残留pTMTVliver对无进展生存的预后表现优于TMTV4和Deauville评分(HR 5.10,C-index 0.724)。
  • 残留pTMTVliver对总生存的预后表现优于TMTV4和Deauville评分(HR 4.00,C-index 0.853)。
  • 单独Deauville评分未能完全反映Deauville评分4-5分患者结局的异质性。

关键数值与推荐

  • pTMTVliver使用200%SUVmeanliver阈值,与125%SUVmaxliver一致。
  • 残留pTMTVliver对无进展生存的HR为5.10,C-index为0.724。
  • 残留pTMTVliver对总生存的HR为4.00,C-index为0.853。
  • 基线TMTV与无进展生存和总生存的关联在所有三种方法中p<0.0001。

局限性

  • 需要更大队列验证这些发现并优化基于残留TMTV的临床应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Total metabolic tumor volume (TMTV) at baseline becomes a key biomarker in several lymphoma subtypes. Variability in segmentation methods such as 41%SUVmax and SUVmax > 4 has limited its clinical application. Additionally, immune-checkpoint-inhibitors introduced challenges in response assessment due to pseudoprogression, complicating the use of traditional metrics. This study investigates the prognostic impact of baseline- and residual-TMTV and introduces a novel personalized-liver-based-threshold (pTMTVliver) to enhance precision in patient stratification. METHODS: We analyzed 91 patients with relapsed/refractory diffuse-large-B-cell lymphoma and follicular lymphoma from the GATA trial, comparing patient's outcome according to three segmentation methods: TMTV41%, TMTV4, and pTMTVliver. pTMTVliver used a threshold of 200%SUVmeanliver aligning with 125%SUVmaxliver to enhance standardization and reduce variability. RESULTS: Baseline-TMTV significantly influenced prognosis with higher TMTV correlating with shorter PFS and OS (p < 0.0001 for all methods). Residual-TMTV, particularly with pTMTVliver and TMTV4, stratified no-CMR patients with the lowest predictive errors and better predictive accuracy compared to TMTV41% Multivariate analyses confirmed residual-pTMTVliver as superior for prognostic performance for PFS (HR:5.10; C-index:0.724) and OS (HR:4.00; C-index:0.853) compared to TMTV4 and Deauville Score (DS). The DS alone did not fully capture the heterogeneity of outcomes of DS4-5 patients. CONCLUSION: Baseline- and residual-TMTV strongly influence prognosis and response in lymphoma patients. The novel personalized pTMTVliver method offers improved accuracy of patient stratification, particularly for those with DS4-5, providing more reliable risk assessment. Larger cohorts are needed to validate these findings and optimize residual-TMTV-based clinical applications.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Malmon S, Casasnovas O, Fournier M, et al. Personalized baseline and residual TMTV influence treatment response and outcomes in relapsed/refractory lymphomas: results from the GATA study. Eur J Nucl Med Mol Imaging. 2025. PMID: 39984744. doi:10.1007/s00259-025-07154-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。